Prevduo Patent Expiration

Prevduo is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 3 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 25, 2038. Details of Prevduo's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11110054 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Oct, 2038

(14 years from now)

Active
US11938217 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Oct, 2038

(14 years from now)

Active
US10456354 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Oct, 2038

(14 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Prevduo's patents.

Given below is the list of recent legal activities going on the following patents of Prevduo.

Activity Date Patent Number
Patent litigations
Patent eGrant Notification 26 Mar, 2024 US11938217
Email Notification 26 Mar, 2024 US11938217
Recordation of Patent Grant Mailed 26 Mar, 2024 US11938217
Patent Issue Date Used in PTA Calculation 26 Mar, 2024 US11938217
Recordation of Patent eGrant 26 Mar, 2024 US11938217
Mail Patent eGrant Notification 26 Mar, 2024 US11938217
Email Notification 07 Mar, 2024 US11938217
Issue Notification Mailed 06 Mar, 2024 US11938217
Dispatch to FDC 26 Feb, 2024 US11938217
Application Is Considered Ready for Issue 26 Feb, 2024 US11938217

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Prevduo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Prevduo's family patents as well as insights into ongoing legal events on those patents.

Prevduo's Family Patents

Prevduo has patent protection in a total of 2 countries. It has a significant patent presence in the US with 80.0% of its patents being US patents. Click below to unlock the full patent family tree for Prevduo.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Prevduo's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 25, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Prevduo Generics:

There are no approved generic versions for Prevduo as of now.





About Prevduo

Prevduo is a drug owned by Azurity Pharmaceuticals Inc. Prevduo uses Glycopyrrolate; Neostigmine Methylsulfate as an active ingredient. Prevduo was launched by Azurity in 2023.

Approval Date:

Prevduo was approved by FDA for market use on 23 February, 2023.

Active Ingredient:

Prevduo uses Glycopyrrolate; Neostigmine Methylsulfate as the active ingredient. Check out other Drugs and Companies using Glycopyrrolate; Neostigmine Methylsulfate ingredient

Dosage:

Prevduo is available in solution form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML) SOLUTION Prescription INTRAVENOUS